Single-Agent PD-1 Blockade Is “Treatment of Choice” for Desmoplastic Melanoma

Data from the phase II S1512 trial indicate that patients with inoperable metastatic desmoplastic melanoma are highly responsive to first-line pembrolizumab. As such, anti-PD-1 monotherapy, rather than current combinations such as nivolumab-relatlimab, should be considered for these patients.